With regard to predictive impact, one-third of the patients of our cohort with high tumour NOTCH1 mRNA expression who were treated with adjuvant chemotherapy experienced relapses within the first five years after diagnosis and had a worse OS probability compared to patients without cytotoxic treatment. This evidence concerns the gene NOTCH1 and neoplasm.